Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 1,345 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Maia Biotechnology Inc | MAIA | AMEX | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.08 | 2.54% | 3.23 | 07:04:06 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.15 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 9 | 1,345 | - | 0.82 - 3.59 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 08:05:28 | 31 | US$ 3.12 | USD |
Maia Biotechnology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 44.77M | 14.21M | - | 0 | -19.77M | -1.39 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Maia Biotechnology News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MAIA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.70 | 3.59 | 2.651 | 3.06 | 518,946 | 0.53 | 19.63% |
| 1 Month | 2.27 | 3.59 | 1.851 | 2.72 | 269,962 | 0.96 | 42.29% |
| 3 Months | 1.42 | 3.59 | 1.24 | 2.14 | 370,874 | 1.81 | 127.46% |
| 6 Months | 2.00 | 3.59 | 0.82 | 1.72 | 380,967 | 1.23 | 61.50% |
| 1 Year | 2.61 | 3.59 | 0.82 | 1.83 | 247,087 | 0.62 | 23.75% |
| 3 Years | 4.10 | 9.64 | 0.82 | 3.36 | 231,340 | -0.87 | -21.22% |
| 5 Years | 4.10 | 9.64 | 0.82 | 3.36 | 231,340 | -0.87 | -21.22% |
Maia Biotechnology Description
| MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells. |
